SW106 is a novel selective antagonist of PTHR1-mediated cAMP signaling, not functioning as an inverse agonist on either PTHR1-H223R or PTHR1-T410P, which have activating mutations at the cytoplasmic ends of TMD helices-2 and -6, respectively.